Search - tctmd.com

Displaying 1 - 20 of 46

Sort: Relevancy | Date

News Daily News

Study Links Osteoporosis Injections and Increased MACE in Dialysis Patients

L.A. McKeown

January 06, 2025

News Daily News

IVC Filter Use Declining, but Retrieval Rates Abysmally Low: SAFE-IVC

Michael O'Riordan

November 11, 2024

News Opinion CV Team Dispatch

September 2024 Dispatch for the CV Team

L.A. McKeown

September 01, 2024

News Conference News SCAI 2024

Women, Black Patients Less Likely to Get Advanced PE Therapy, Analysis Shows

L.A. McKeown

May 06, 2024

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

L.A. McKeown

April 16, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Opinion CV Team Dispatch

November 2023 News Roundup

L.A. McKeown

November 01, 2023

News Conference News CRT 2023

Renal Denervation in Black Patients: SYMPLICITY HTN 3 Reassures at 36 Months

Yael L. Maxwell

February 28, 2023

News Daily News

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Michael O'Riordan

December 20, 2022

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

Todd Neale

November 09, 2022

News Opinion CV Team Dispatch

September 2022 News Roundup

L.A. McKeown

September 01, 2022

News Opinion CV Team Dispatch

January 2022 News Roundup

L.A. McKeown

January 01, 2022

News Conference News ACC 2021

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

Michael O'Riordan

May 16, 2021

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

News Conference News ACC 2019

Renal Denervation May Lower Treatment Burden, as Well as Blood Pressure: RADIANCE-HTN SOLO

Michael O'Riordan

April 01, 2019

News Daily News

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

Michael O'Riordan

December 06, 2018

News Conference News EuroPCR 2018

Two Sham-Controlled Renal Denervation Studies Offer Hope in Hypertension

Michael O'Riordan

May 23, 2018

News Daily News

No IV Hydration for Contrast Nephropathy? AMACING Trial Challenges a Cornerstone of Prophylaxis

Shelley Wood

March 06, 2017

Advertisement

Study Links Osteoporosis Injections and Increased MACE in Dialysis Patients

IVC Filter Use Declining, but Retrieval Rates Abysmally Low: SAFE-IVC

September 2024 Dispatch for the CV Team

Women, Black Patients Less Likely to Get Advanced PE Therapy, Analysis Shows

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

Top Endovascular News of 2023

November 2023 News Roundup

Renal Denervation in Black Patients: SYMPLICITY HTN 3 Reassures at 36 Months

Reduction in BP Drives Treatment Preference for Hypertensive Patients

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

September 2022 News Roundup

January 2022 News Roundup

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Renal Denervation May Lower Treatment Burden, as Well as Blood Pressure: RADIANCE-HTN SOLO

FDA Charts Path for ‘Resurrection’ of Device-Based Antihypertensive Therapies

Two Sham-Controlled Renal Denervation Studies Offer Hope in Hypertension

No IV Hydration for Contrast Nephropathy? AMACING Trial Challenges a Cornerstone of Prophylaxis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content